Safety and Efficacy of Pembrolizumab in US Patients Enrolled in KEYNOTE-030, an Expanded Access Program

Romina P. Oxborough(University of California, San Francisco), April K.S. Salama(Duke University), Michael A. Postow(Memorial Sloan Kettering Cancer Center), Anna M. Pavlick, Adil Daud(University of California, San Francisco), Debra Kush(Merck & Co., Inc., Rahway, NJ, USA (United States)), Mihaela Gazdoiu(Novartis (Switzerland)), Roxana Dronca(Dana-Farber Cancer Institute), Omid Hamid(Cedars-Sinai Medical Center), Richard W. Joseph(Daiichi Sankyo (United States)), Rosemarie Mick(University of Pennsylvania), Steven O’Day(Saint John's Health Center), F. Stephen Hodi(Harvard University), Wen‐Jen Hwu(The University of Texas MD Anderson Cancer Center), Scot Ebbinghaus(Merck & Co., Inc., Rahway, NJ, USA (United States)), Tara C. Gangadhar(University of Pennsylvania), Mario Sznol(Yale University)

Unknown

January 1, 2015

Cited by 0

|New England Journal of Medicine|2012|12.6k

|New England Journal of Medicine|2012|8k

|New England Journal of Medicine|2011|7.7k

|New England Journal of Medicine|2015|5.9k

|New England Journal of Medicine|2013|4.2k

Related Papers